| Not Yet Recruiting | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast C NCT06251544 | Baylor College of Medicine | Phase 1 |
| Recruiting | A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer ( NCT07067138 | National Cancer Institute (NCI) | N/A |
| Active Not Recruiting | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer NCT06878248 | Calibr, a division of Scripps Research | Phase 1 |
| Active Not Recruiting | A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer NCT06495164 | Pfizer | — |
| Recruiting | Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors NCT03463954 | Novian Health Inc. | N/A |
| Unknown | Low-field MRI for Breast Cancer Screening NCT05486520 | Massachusetts General Hospital | N/A |
| Active Not Recruiting | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresec NCT05033756 | Institut fuer Frauengesundheit | Phase 2 |
| Unknown | Therapeutic Dose Monitoring (TDM) of Tamoxifen NCT05133674 | Karolinska University Hospital | Phase 2 |
| Completed | Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) NCT05159778 | HiberCell, Inc. | Phase 2 |
| Completed | Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors NCT05364450 | Indiana University | N/A |
| Recruiting | Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early NCT04669873 | Instituto Brasileiro de Controle do Cancer | N/A |
| Recruiting | Swedish Ibrance Registries Insights (SIRI) NCT04654208 | Pfizer | — |
| Completed | MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery NCT04327063 | Institut Curie | Phase 3 |
| Withdrawn | Breast Reconstruction Following Breast Cancer in Very High Risk Patients NCT03261323 | Case Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT NCT03435952 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC NCT03289819 | Institut fuer Frauengesundheit | Phase 2 |
| Completed | Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressin NCT03366428 | Daiichi Sankyo Co., Ltd. | Phase 1 |
| Active Not Recruiting | An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer NCT03429907 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer NCT03379428 | US Oncology Research | Phase 1 / Phase 2 |
| Active Not Recruiting | Selumetinib and Olaparib in Solid Tumors NCT03162627 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ibrance Real World Insights NCT03159195 | Pfizer | — |
| Withdrawn | Lenvatinib and Capecitabine in Patients With Advanced Malignancies NCT02915172 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment NCT02891681 | Washington University School of Medicine | N/A |
| Completed | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breas NCT03425656 | AryoGen Pharmed Co. | Phase 3 |
| Completed | Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors NCT02611544 | Indiana University | N/A |
| Completed | MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery NCT02408393 | Institut Curie | Phase 3 |
| Completed | Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients NCT02495363 | Rabin Medical Center | — |
| Completed | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Canc NCT02187991 | US Oncology Research | Phase 2 |
| Active Not Recruiting | Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant End NCT02204098 | Washington University School of Medicine | Phase 1 |
| Completed | Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Do NCT02378337 | Hospital Sao Rafael | — |
| Completed | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer NCT02101385 | Bryan Schneider, MD | Phase 2 |
| Completed | Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Can NCT01953003 | Pierre Fabre Medicament | Phase 3 |
| Completed | Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors NCT01639911 | University of Illinois at Chicago | Phase 1 |
| Unknown | Isolation and Characterization of Cancer Stem Cells Using iFP Technique NCT01641003 | Rambam Health Care Campus | — |
| Unknown | ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes NCT01395706 | Pulsion Medical Systems SE | Phase 2 |
| Completed | Discordant Hormonal Status of Breast Cancer. NCT01943032 | National Cancer Institute, Thailand | — |
| Completed | Discordant HER2/Neu Status of Breast Cancer. NCT01935739 | National Cancer Institute, Thailand | — |
| Terminated | A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Canc NCT02131506 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 1 |